News from REMEDY

Diakonhjemmet Sykehus was awarded funds from Helse Sør-Öst for eight research projects, four of which are part of REMEDY. Three of the studies receiving funding are linked to remote monitoring/eHealth, while the fourth is a clinical study on hip fractures.

The Nor-vaC study concludes that repeated covid vaccination is safe and that it strengthens the antibody response in patients with inflammatory diseases of the joints and intestines.

Researcher Nina Østerås has presented the new research-based advice for osteoarthritis in VG. She emphasizes that even if the joints are characterized by osteoarthritis, movement and organized exercise will lead to better joint health.

As part of the European SQUEEZE collaboration, REMEDY receives 13 million to investigate therapeutic drug monitoring.

On the 20th-21st In September, a start-up seminar was organized in REMEDY. The seminar lays the foundation for further collaboration to research rheumatic and musculoskeletal diseases in the future.

On the international Clinical Trials day (May 20), the Research Center for Treatment in Rheumatology and Musculoskeletal Diseases (REMEDY) was officially declared open at Diakonhjemmet Hospital. The REMEDY center is supported by research funds from the Research Council of Norway and the Olav Thon Foundation

In competition with many strong research environments in Norway, the Research Council has awarded Diakonhjemmet hospital up to NOK 128 million to establish a research center for treatment in rheumatology and musculoskeletal diseases. This research effort will provide better treatment for a large patient group.